Electrocardiographic changes and halofantrine plasma level during acute falciparum malaria

American Journal of Tropical Medicine and Hygiene

Volumn 54, Issue 3, 1996, Pages 225-228

  Touze, J E ^a   Bernard, J ^b   Keundjian, A ^a   Imbert, P ^a   Viguier, A ^b   Chaudet, H ^c   Doury, J C ^a  

^a Tropical Med Inst for French Army   (France)

^b SERVICE DE PNEUMOLOGIE   (France)

^c HÔPITAL NORD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; DRUG METABOLITE; HALOFANTRINE; MEFLOQUINE;

ADULT; AMBULATORY MONITORING; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ELECTROCARDIOGRAPHY MONITORING; HEART VENTRICLE ARRHYTHMIA; HUMAN; INCIDENCE; LONG QT SYNDROME; MALARIA FALCIPARUM; MALE; ORAL DRUG ADMINISTRATION; PLASMODIUM FALCIPARUM;

EID: 0029873967     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1996.54.225     Document Type: Article

References (21)

1. Wirima J, Khoromana C, Molyneux ME, Gilles HM, 1988. Clinical trials with halofantrine hydrochloride in Malawi. Lancet ii: 250-252.
2. Cosgriff TM, Boudreau EF, Pamilin CL, Doberstyn EB, Desjarjins RE, Canfield CJ, 1982. Evaluation of the antimalarial activity of the pheneanthrenemethanol halofantrine (WR 171,669). Am J Trop Med Hyg 31: 1075-1079.
3. ter Kuile FO, Dolan G, Nosten F, Edstein MD, Luxemburger C, Phaijun L, Chongsuphajaisiddhi T, Webster HK, White NJ, 1993. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet 341: 1044-1049.
4. Nosten F, ter Kuile FO, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, White NJ, 1993. Cardiac effects of antimalarial treatment with halofantrine. Lancet 341: 1054-1056.
5. Castot A, Rapoport P, Le Coz P, Monlun E, Pillet J, Cochard JF, Le Bras M, 1993. Prolonged QT interval with halofantrine. Lancet 341: 1541-1542.
6. Touze JE, Deharo JC, Imbert P, Fourcade L, Van de Walle JP, Djiane P, 1994. Potentiels tardifs ventriculaires et traitement antimalarique par halofantrine. Presse Med 23: 1450-1451.
7. World Health Organization, 1990. Severe and complicated falciparum malaria. Trans R S Med Hyg 84 (suppl 2): 1-65.
8. Ahnve S, 1985. Correction of the QT interval for heart rate: review of different formulas and the use of Bazett's formula in myocardial infarction. Am Heart J 109: 568-574.
9. Simson MB, 1986. Use of signals in the terminal QRS complex to identify patients with ventricular tachycardia after myocardial infarction. Circulation 74: 731-745.
10. Breithardt G, Gain ME, El-Sherif N, 1991. Standards for analysis of ventricular late potentials using high resolution of the signal-averaged electrocardiography. J Am Coll Cardiol 17: 999-1006.
11. Bryson M, Goa KL, 1992. Halofantrine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic potential. Drugs 43: 236-258.
12. Roden DM, Thompson KA, Hoffman BF, Woosley R, 1986. Clinical features and basic mechanisms of quinidine-induced arrythmias. J Am Coll Cardiol 8 (suppl A): A73-A78.
13. Freedman RA, Steinberg JS, 1991. Selective prolongation of QRS late potentials by sodium channel blocking antiarrythmic drugs: relation to slowing of ventricular tachycardia. J Am Coll Cardiol 17: 1017-1025.
14. Tobe JM, De Langen CDJ, Bink-Boelkens MThE, Mook PH, Viersma JW, Lie K, Wesseling H, 1992. Late potentials in a bradycardia-dependent long QT syndrome associated with sudden death during sleep. J Am Coll Cardiol 19: 541-549.
15. Broom C, 1989. Human pharmacokinetic s of halofantrine hydrochloride. Warhurst DC, Schofield CJ, eds. Halofantrine in the Treatment of Multidrug Resistant Malaria. Parasitology Today (suppl): 15-20.
16. Karbwang J, Na Bangchang K, 1994. Clinical pharmacokinetics of halofantrine. Clin Pharmacokinet 27: 104-119.
17. Boudreau EF, Pang LW, Dixon KE, Webster HK, Pavand K, Tosingha L, Somutsakorn P, Canfield CJ, 1988. Malaria: treatment efficacy of halofantrine (WR 171,669) in initial field trials in Thailand. Bull World Health Organ 66: 227-235.
18. Karbwang J, Milton KA, Na Bangchang K, Ward SA, Edwards G, Bunnag D, 1991. Pharmacokinetics of halofantrine in Thai patients with acute uncomplicated falciparum malaria. Br J Clin Pharmacol 31: 484-487.
19. Wildling E, Winkler S, Brandts C, Jenne L, Graninger W, Wernsdorfer WH, Bienzle U, Kremsner PG, 1993. Halofantrine sensitivity. Lancet 342: 55.
20. Gillespie SH, Msaki EP, Ramsay A, Ngowi FL, Fox R, 1993. A new micronized formulation of halofantrine hydrochloride in the treatment of acute Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 87: 467-469.
21. Bouchaud O, Basco LK, Gillotin C, Gimenez F, Ramiliarisoa O, Genissel B, Bouvet E, Farinotti R, Le Bras J, Coulaud JP, 1994. Clinical efficacy and pharmacokinetics of micronized halofantrine for the treatment of acute uncomplicated falciparum malaria in nonimmune patients. Am J Trop Med Hyg 51: 204-213.